Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022

open access

Vol 82, No 4 (2011)
ARTICLES
View PDF Download PDF file
Get Citation

The somatotropic axis in postmenopausal women during six month of transdermalcontinuous 17β-estradiol administration combined with oral medroxyprogesterone

Tomasz Milewicz, Józef Krzysiek, Iwona Rogatko, Krystyna Sztefko, Ewa Stochmal, Alicja Hubalewska-Dydejczyk, Robert Jach, Stanisław Radowicki
Ginekol Pol 2011;82(4).

open access

Vol 82, No 4 (2011)
ARTICLES

Abstract

Abstract Aim: The evaluation of the influence of continuous transdermal estradiol supplementation combined with oral medroxyprogesterone on the somatotropic axis in postmenopausal women. Material and methods: 25 women completed the study. Group A – 13 women received transdermal 17β-estradiol(Oesclim 50 - Fournier-Solvay) combined with oral 5 mg daily medroxyprogesterone (Gestomikron - Adamed).Group B - 12 women without treatment. Basic plasma FSH, estradiol, glucose, insulin, SHBG, hGH, total and freeIGF-I, IGFBP-1 as well as IGFBP-3 were measured initially and at the 12th and 24th week of the study. Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in group A during estradiol supplementation. Mean plasma level of free IGF-I and free to total IGF-I ratio were increased in group A during 24 weeks of hormone therapy. In the control group (group B) there was the significant increase in mean plasma IGFBP-3 level. Other parameters showed no significant changes in the control group. Conclusion: The administration of transdermal 17β-estradiol combined with oral medroxyprogesterone increases the IGF-I bioavailability. However this influence do not exceed the physiologial level of IGF-I bioavailability.

Abstract

Abstract Aim: The evaluation of the influence of continuous transdermal estradiol supplementation combined with oral medroxyprogesterone on the somatotropic axis in postmenopausal women. Material and methods: 25 women completed the study. Group A – 13 women received transdermal 17β-estradiol(Oesclim 50 - Fournier-Solvay) combined with oral 5 mg daily medroxyprogesterone (Gestomikron - Adamed).Group B - 12 women without treatment. Basic plasma FSH, estradiol, glucose, insulin, SHBG, hGH, total and freeIGF-I, IGFBP-1 as well as IGFBP-3 were measured initially and at the 12th and 24th week of the study. Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in group A during estradiol supplementation. Mean plasma level of free IGF-I and free to total IGF-I ratio were increased in group A during 24 weeks of hormone therapy. In the control group (group B) there was the significant increase in mean plasma IGFBP-3 level. Other parameters showed no significant changes in the control group. Conclusion: The administration of transdermal 17β-estradiol combined with oral medroxyprogesterone increases the IGF-I bioavailability. However this influence do not exceed the physiologial level of IGF-I bioavailability.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

hGH, IGF-1, IGFBP-3, postmenopause

About this article
Title

The somatotropic axis in postmenopausal women during six month of transdermalcontinuous 17β-estradiol administration combined with oral medroxyprogesterone

Journal

Ginekologia Polska

Issue

Vol 82, No 4 (2011)

Page views

480

Article views/downloads

553

Bibliographic record

Ginekol Pol 2011;82(4).

Keywords

hGH
IGF-1
IGFBP-3
postmenopause

Authors

Tomasz Milewicz
Józef Krzysiek
Iwona Rogatko
Krystyna Sztefko
Ewa Stochmal
Alicja Hubalewska-Dydejczyk
Robert Jach
Stanisław Radowicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl